Kras Mutation Detection, Tissue/Block

What is KRAS mutation detection test?

KRAS is an important gene involved in cell growth and signalling. Mutations in KRAS are commonly found in colorectal, lung, and pancreatic cancers. KRAS mutation detection test analyzes tumor tissue (FFPE blocks) to detect mutations in the KRAS gene using molecular techniques such as Real time PCR. KRAS mutation detection test identifies specific KRAS mutations that may influence treatment decisions—especially use of anti-EGFR therapies.

Why consider KRAS mutation detection test?

• To determine eligibility for targeted therapies, especially in colorectal cancer: KRAS-mutated tumors do not respond to anti-EGFR drugs like cetuximab or panitumumab.
• Helps guide personalized treatment plans and avoid ineffective therapies.
• Provides prognostic information in several cancers.
• Useful for molecular profiling and inclusion in clinical trials.

Who should get tested for KRAS mutation detection test?

• Patients with colorectal cancer (especially metastatic), Non-small cell lung cancer (NSCLC) and pancreatic cancer etc.
• Individuals being considered for targeted therapy.
• When detailed tumor mutation profiling is required.
• Oncologists seeking to tailor treatment based on tumor genetics.

More Information

OTHER NAMES: KRAS Gene Mutation Test, KRAS PCR Test (Tumor Block), FFPE Tissue KRAS Testing, KRAS Somatic Mutation Analysis, KRAS Genetic Profiling (Tumor Tissue)

KRAS is a gene that makes a protein involved in cell growth and division. When mutated, it can lead to uncontrolled cell division, contributing to cancer. KRAS mutations are found in about 35–45% of colorectal cancers, especially in exons 2, 3, and 4 (codons 12, 13, 61, 146).